Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trial

Reid W. Merryman, Joshua Brody, Jennifer R. Brown et al.|Blood|2025

Cited by 0